TECENTRIQ (atezolizumab) authorized for Canadians with early non-small cell lung cancer

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 14, 2022, Health Canada has authorized TECENTRIQ® (atezolizumab) as - Click here if this is your press release! - Travel News | eTurboNews | eTN

Related Keywords

Canada ,Quebec ,Canadians ,Loredana Regep ,Shem Singh ,Peter Glazier ,Lung Health Foundation ,Roche Limited Canada ,Regulatory Affairs ,Health Canada ,Hoffmann La Roche Limited ,Roche Canada ,Programmed Death ,Executive Director Lung Cancer ,Executive Vice President ,Lung Health ,Vice President ,Hoffmann La Roche ,